Nanexa AB (publ) (NANEXA.ST)
SEK 2.54
(-5.22%)
SEK 2.54
(-5.22%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -61.13 Million SEK | 18.39% |
| 2022 | -74.91 Million SEK | 26.43% |
| 2021 | -101.82 Million SEK | -1056.48% |
| 2020 | -8.8 Million SEK | -41.49% |
| 2019 | -6.22 Million SEK | -26.25% |
| 2018 | -4.92 Million SEK | 73.01% |
| 2017 | -18.26 Million SEK | -61.16% |
| 2016 | -11.33 Million SEK | -285.78% |
| 2015 | -2.93 Million SEK | -943.47% |
| 2014 | 348.23 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -24.77 Million SEK | -125.04% |
| 2024 Q1 | -11 Million SEK | 81.99% |
| 2023 Q2 | -15.38 Million SEK | 58.41% |
| 2023 Q4 | -61.13 Million SEK | -236.76% |
| 2023 FY | -61.13 Million SEK | 18.39% |
| 2023 Q1 | -36.98 Million SEK | 50.63% |
| 2023 Q3 | -18.15 Million SEK | -18.02% |
| 2022 Q2 | -61.23 Million SEK | 28.31% |
| 2022 Q3 | -41.05 Million SEK | 32.96% |
| 2022 FY | -74.91 Million SEK | 26.43% |
| 2022 Q4 | -74.91 Million SEK | -82.47% |
| 2022 Q1 | -85.41 Million SEK | 16.11% |
| 2021 Q3 | -116.91 Million SEK | -362.76% |
| 2021 Q1 | -32.25 Million SEK | -266.36% |
| 2021 Q2 | -25.26 Million SEK | 21.68% |
| 2021 FY | -101.82 Million SEK | -1056.48% |
| 2021 Q4 | -101.82 Million SEK | 12.9% |
| 2020 Q4 | -8.8 Million SEK | 61.52% |
| 2020 FY | -8.8 Million SEK | -41.49% |
| 2020 Q2 | -30.72 Million SEK | 23.99% |
| 2020 Q1 | -40.41 Million SEK | -549.45% |
| 2020 Q3 | -22.88 Million SEK | 25.52% |
| 2019 Q2 | -16.41 Million SEK | 20.43% |
| 2019 Q3 | -12.91 Million SEK | 21.34% |
| 2019 FY | -6.22 Million SEK | -26.25% |
| 2019 Q4 | -6.22 Million SEK | 51.8% |
| 2019 Q1 | -20.62 Million SEK | -318.49% |
| 2018 Q3 | -8.88 Million SEK | 24.95% |
| 2018 FY | -4.92 Million SEK | 73.01% |
| 2018 Q1 | -15.18 Million SEK | 16.87% |
| 2018 Q2 | -11.83 Million SEK | 22.03% |
| 2018 Q4 | -4.92 Million SEK | 44.51% |
| 2017 Q4 | -18.26 Million SEK | -543.45% |
| 2017 FY | -18.26 Million SEK | -61.16% |
| 2017 Q3 | -2.83 Million SEK | 42.7% |
| 2017 Q2 | -4.95 Million SEK | 42.94% |
| 2017 Q1 | -8.68 Million SEK | 23.39% |
| 2016 FY | -11.33 Million SEK | -285.78% |
| 2016 Q1 | -1.23 Million SEK | 57.82% |
| 2016 Q2 | -18.83 Million SEK | -1419.85% |
| 2016 Q4 | -11.33 Million SEK | 23.8% |
| 2016 Q3 | -14.87 Million SEK | 21.03% |
| 2015 FY | -2.93 Million SEK | -943.47% |
| 2015 Q3 | -4.5 Million SEK | 31.75% |
| 2015 Q4 | -2.93 Million SEK | 34.86% |
| 2015 Q2 | -6.6 Million SEK | -382670.93% |
| 2015 Q1 | 1727.00 SEK | -99.5% |
| 2014 FY | 348.23 Thousand SEK | 0.0% |
| 2014 Q4 | 348.23 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AcuCort AB | -19.24 Million SEK | -217.689% |
| AlzeCure Pharma AB (publ) | -29.1 Million SEK | -110.089% |
| BioGaia AB (publ) | -1.53 Billion SEK | 96.018% |
| Enzymatica AB (publ) | 17.73 Million SEK | 444.681% |
| Enorama Pharma AB (publ) | -5.71 Million SEK | -969.372% |
| Gabather AB (publ) | -1.11 Million SEK | -5383.049% |
| Klaria Pharma Holding AB (publ.) | 17.68 Million SEK | 445.694% |
| Moberg Pharma AB (publ) | -55.81 Million SEK | -9.527% |
| Newbury Pharmaceuticals AB (publ) | -15.3 Million SEK | -299.503% |
| ODI Pharma AB | -2.63 Million SEK | -2217.596% |
| Orexo AB (publ) | 302.8 Million SEK | 120.19% |
| Probi AB (publ) | -275.85 Million SEK | 77.837% |
| Swedencare AB (publ) | 1.42 Billion SEK | 104.301% |
| Swedish Orphan Biovitrum AB (publ) | 19.58 Billion SEK | 100.312% |
| Toleranzia AB | -17.45 Million SEK | -250.269% |
| Vivesto AB | -1.29 Million SEK | -4606.39% |